Medifast (NYSE:MED) Updates Q1 2025 Earnings Guidance

Medifast (NYSE:MED) updated its first quarter 2025 earnings guidance on Tuesday. The company provided EPS guidance of -0.500-0.000 for the period, compared to the consensus EPS estimate of -0.190. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.8 million.

Medifast Stock Performance

Medifast stock traded down $0.16 during mid-day trading on Tuesday, hitting $16.05. 280,528 shares of the company’s stock traded hands, compared to its average volume of 212,304. The company has a quick ratio of 2.55, a current ratio of 3.11 and a debt-to-equity ratio of 0.06. Medifast has a one year low of $14.76 and a one year high of $49.90. The firm has a 50 day moving average price of $16.61 and a 200 day moving average price of $18.05. The company has a market cap of $175.55 million, a PE ratio of 24.32 and a beta of 1.14.

Medifast (NYSE:MED) last posted its quarterly earnings data on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.26. Medifast had a net margin of 1.09% and a return on equity of 15.98%. On average, equities analysts forecast that Medifast will post 1.68 EPS for the current year.

Wall Street Analyst Weigh In

Separately, DA Davidson raised Medifast from an “underperform” rating to a “neutral” rating and boosted their price objective for the stock from $16.50 to $17.00 in a research note on Tuesday, November 5th.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.